Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism Isabelle Mahé, M.D.,…
Ler MaisExtended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism Isabelle Mahé, M.D.,…
Ler MaisThe efficacy and safety of low-molecular-weight heparins for venous thromboembolism…
Ler MaisMitochondrial DNA copy number and its association with venous thromboembolism…
Ler MaisNatural history of untreated acute pulmonary embolism in patients with…
Ler MaisUnveiling the trends: Growing cancer and venous thromboembolism mortality in…
Ler MaisRisk assessment and prevention of cancer-associated venous thromboembolism in ambulatory…
Ler MaisChemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired…
Ler MaisTime trends of outcome and treatment options for disseminated intravascular…
Ler MaisPredictors of recurrent venous thromboembolism and major bleeding in patients…
Ler MaisEmbolic strokes of undetermined source: a clinical consensus statement of…
Ler Mais